Monday, 18 Feb 2019

You are here

Not All Hyperuricemia Leads to Gout

Dalbeth and colleagues studied 4 large prospective cohorts and found that rising levels of serum uric acid (SUA) leads to a non-linear increased risk of incident gout, but only half of those with SUA ≥10mg/dL developed clinically evident gout. 

Researchers analyzed four prospective cohorts (Atherosclerosis Risk in Communities Study, Coronary Artery Risk Development in Young Adults Study, and both the Original and Offspring cohorts of the Framingham Heart Study)  to assess the correlation between baseline SUA and the risk of incident gout.

There were 18 889 gout-free participants followed for a mean 11.2  years of follow-up.

The cumulative 15 year incidence of new gout cases varied according to baseline SUA:

  • SUA 6 mg/dL = 1.1% (0.9 to 1.4) 
  • SUA ≥10 mg/dL = 49% (31 to 67)

The adjusted hazard ration for incident gout was:

  • SUA 6.0-6.9 mg/dL - HR 2.7
  • SUA 7.0-7.9 mg/dL  - HR  6.6
  • SUA 8.0-8.9 mg/dL  - HR 15
  • SUA  9.0-9.9 mg/dL - HR 30
  • SUA ≥10 mg/dL - HR  64.

While hyperuricemia plays a significant role in causing gout, there are other factors, over time that along with prolonged hyperuricemia are necessary to lead to gout.

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

U.S. Gout Rates Remain Steady, but Substantial

Using data from 5,467 adults in the US in the National Health and Nutrition Examination Survey (NHANES) for the years 2007-2016, researchers found that the prevalence of gout and hyperuricemia has remained at 3.9%, having doubled from the 1960s to the 1990s, corresponding to an estimated 9.2 million adults with gout in 2015-2016.

Febuxostat Gets Reprieve from FDA Advisory Panel

On January 11, 2019 the FDA convened two advisory panels (the Arthritis Advisory Committee [AAC] and the Drug Safety and Risk Management Advisory Committee [DSaRM]) to consider the cardiovascular safety of febuxostat (Uloric) based on the 2018 “Cardiovascular Safety of Febuxostat and Allopurinol in Patients with Gout and Cardiovascular Morbidities (CARES) study. 

The Vote

Only One-Third of Gout Patients Receive Urate-Lowering Drugs

The most recent analysis of National Health and Nutrition Examination Survey [NHANES] 2007-2016) data shows the prevalence of gout to be 9.3 million in the USA.

Data from 5,467 participants from NHANES 2015-2016, finds gout in 3.9% or  9.2 million US adults.  This includes 5.2% [5.9 million] of men and 2.7% [3.3 million] of  women with gout.

Sleep Apnea Increases Gout Risk

Both Gout and obstructive sleep apnea (OSA) comingle with a wide range of serious comorbidities. A matched retrospective cohort study from the UK Clinical Practice Research database shows those with OSA are at a higher risk of developing gout.

This report compared 15,879 patients with OSA versus 63,296 without; median follow‐up was 5.8 years.

Hepatic Safety of Urate Lowering Therapies in Gout

Lee and a group of Korean investigators have analyzed the comparative safety of allopurinol and febuxostat in a small cohort of gout patients with fatty liver disease (FLD) and found febuxostat had a lower risk for hepatotoxicity (defined as AST or ALT at least 3× the upper limit of normal) compared to allopurinol.